What Pharma Needs Next Titelbild

What Pharma Needs Next

What Pharma Needs Next

Von: Veeva Systems
Jetzt kostenlos hören, ohne Abo

Nur 0,99 € pro Monat für die ersten 3 Monate

Danach 9.95 € pro Monat. Bedingungen gelten.

Über diesen Titel

What Pharma Needs Next is a podcast for commercial and medical leaders. You’ll hear from life sciences experts on the trends re-shaping biopharma, how technology and data are accelerating their vital work, and ways to improve customer-centricity in the face of HCP and KOL access challenges.© Copyright 2024 Veeva Systems Wissenschaft Ökonomie
  • UCB and Takeda: Improving the Customer Experience through Medical-Commercial Collaboration
    Oct 6 2025

    What happens when medical and commercial teams truly align? Stronger launches, a smoother HCP experience, and better patient outcomes. In this episode, Christoph Bug speaks with Pascal Vande Gucht of UCB and Georgios Tramountanis of Takeda about breaking down silos and creating unified, cross-functional strategies. They explore how visibility, shared messaging, and thoughtful change management fuel collaboration–and how tools like GenAI and data platforms are driving the next wave of transformation.

    Mehr anzeigen Weniger anzeigen
    22 Min.
  • Turning Content into Memorable Customer Experiences
    Jun 4 2025

    How does great content become memorable customer experiences in life sciences? Erica Taylor and Oz Demir of Genentech share their recent experiences of spearheading marketing transformation, including success factors as you get started and how to think about behavioral change. They explain the novel ways their teams are using data and automation to deliver on business goals to quickly scale personalized content for customers.

    Mehr anzeigen Weniger anzeigen
    22 Min.
  • Preparing for a Faster Trial-to-Treatment Pathway
    Nov 29 2024

    Pharmaphorum’s Nicole Raleigh interviews Chris Moore, president of Veeva Europe, on trends shaping commercial life sciences. Chris highlights AI’s potential use cases, the need for caution, and how commercial and medical leaders are overcoming access challenges to accelerate treatment pathways.

    Mehr anzeigen Weniger anzeigen
    27 Min.
Noch keine Rezensionen vorhanden